blinatumomab April 12, 2017 blinatumomab Trade Name Orphan Indication Treatment for hairy cell leukemia USA Market Approval USA USA Designation Date 2008-05-16 00:00:00 Sponsor Amgen, Inc.;One Amgen Center Drive;Thousand Oaks, California
